Aim: To determine the risk of amputations associated with sodium-glucose co-transporter-2 inhibitors (SGLT2i) relative to dipeptidyl peptidase-4 inhibitors (DPP4i).
| INTRODUCTION
Patients with type 2 diabetes experience poor outcomes in the presence of other metabolic risk factors. 1 Newer treatments associated with reductions in body weight and cardiovascular benefits are of particular interest given the increasing prevalence of patients with type 2 diabetes and metabolic disease. 2 Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are one such new class of drugs that lower the concentration of plasma glucose by preventing its resorption in the proximal renal tubule and thereby promoting glucosuria. Clinical trials with SGLT2i report significant reductions in HbA1c, body weight, systolic blood pressure, and major adverse cardiac events. [3] [4] [5] [6] [7] [8] [9] In 2016, the United States (U.S.) Food and Drug Administration (FDA) issued a safety alert regarding amputations associated with canagliflozin. The alert was based on a 2-fold increase in risk reported in the Canagliflozin Cardiovascular Assessment Study (CANVAS) program. 10 The CANVAS program included 10 142 patients who were 30 years or older with type 2 diabetes and at risk for cardiovascular disease. 9 Over a median follow-up of 2.4 years, rates of amputations were significantly higher in those randomized to canagliflozin (6.3/1000 patient-years) compared to placebo (3.4/1000 patientyears) resulting in a hazard ratio (HR) of 1.97 (95% CI 1.41-2.75).
The risk for amputations was not observed in non-CANVAS trials of canagliflozin or in trials with other agents in this class, dapagliflozin and empagliflozin. [11] [12] [13] Potential reasons for discrepancies observed in the findings of these trials have been discussed elsewhere. 11 Moreover, due to the low generalizability of findings from clinical trials, early evidence needs to be supplemented with observational data from real-world settings to inform decision making. [14] [15] [16] [17] as second-or third-line oral agents in the management of hyperglycaemia. [24] [25] [26] The purpose of our study was to investigate the association between incident use of SGLT2i and amputations, compared with incident use of DPP4i in a real-world setting.
| MATERIALS AND METHODS
We conducted an active comparator, new user cohort study using data from the 2009 to 2015 Truven Health MarketScan Commercial and Medicare Supplemental Databases.
| Data source
The MarketScan databases capture healthcare utilization of 50 million enrollees in plans run by approximately 350 private-sector employers and payers across the United States. 27 The data include adjudicated claims from inpatient admissions, outpatient services, outpatient prescription drug dispensing, and enrollment information. We excluded baseline use of insulin in order to select patients at comparable duration and severity of diabetes. We excluded patients with long hospitalizations at baseline as we were unable to observe inpatient drug utilization in our data. Since patients with renal impairment are contraindicated for treatment with SGLT2i, we excluded them to avoid any bias introduced via channeling.
| Study population

| Outcome
The outcome was defined as an occurrence of any amputation following treatment initiation. Amputations were identified using Interna- (Table S1 , Supporting Information). The aetiology of amputations was determined using diagnosis codes accompanying the procedure, 28 and hierarchically classified as trauma, cancer, vascular-related, or other. If diagnosis codes for diabetes were also present, aetiology was further described as diabetes-related.
| Follow-up
Patients were followed from their index date until the earliest occurrence of any amputation, treatment discontinuation, switching from 
| Confounding control
High dimensional propensity scores (hdPS) were used to control for potential confounding. 29, 30 Exposure propensity scores were constructed using a semi-automated approach that empirically selected the top 500 covariates across domains of diagnoses (inpatient and outpatient), procedures (inpatient and outpatient), and drug dispensings (outpatient) ranked in order of their magnitude of association with exposure. In addition to high dimensional covariate selection, the following baseline factors were pre-specified in the final exposure propensity score model: age, gender, calendar year of treatment initiation, adapted Diabetes Complications and Severity Index (aDCSI), 31 antidiabetic medication use, presence of diabetic foot injuries 32 or peripheral vascular disease, and history of amputations. We compared the discriminative abilities of models with and without predefined and empirically selected covariates using the concordance statistic. We assessed for multicollinearity by checking the variance inflation factor for each covariate. Patients were matched 1:1 on hdPS using a nearest neighbour approach and a caliper width of 0.2 standard deviations of the logit of the propensity score. 33 The balance of characteristics at baseline between index and comparator groups was assessed before and after propensity score matching using standardized differences. A threshold of 10% was used to identify important differences between the two groups. 34 
| Statistical analysis
The number of amputations and incidence rates per 1000 personyears were determined in the matched cohort, overall and by treatment groups. A univariate Cox Proportional Hazards model was used to estimate the hazard ratio and robust 95% confidence intervals for the effect of SGLT2i on the risk of amputations. 35 The stratified logrank test was used to evaluate the proportionality assumption of the Cox model.
| Subgroup analyses
The risk of amputations was estimated separately in subgroups determined a priori. Dichotomous subgroups for age (>=66 years, <66 years), complications of diabetes (defined as the presence of any vascular complication of diabetes in the aDCSI), and peripheral vascular disease (present, absent) were created from the full study cohort and then hdPS were estimated in each subgroup separately. 36 Matching was performed within each subgroup and hazard ratios were estimated as described above. Lastly, since the safety signal for amputations is with canagliflozin, we assessed the effect of the type of SGLT2i (canagliflozin or non-canagliflozin, separately) in the primary matched cohort.
| Sensitivity analyses
Several sensitivity analyses were performed to evaluate the robustness of our findings to methodological assumptions. First, the definition of outcome was restricted to include only non-traumatic belowknee level amputations. Second, the gap used to define treatment discontinuation was reduced to 15 days to reflect the empirical distribution of medication refill patterns in our data. In the primary analysis, patients were no longer at risk for amputations when their treatment ended. Given that there is no known information on the time of onset for amputations, we extended risk periods 5 to 180 days after the end of treatment to evaluate any potential late effects. All of these analyses were performed on the primary matched cohort. Additionally, other approaches for confounding control with hdPS (1:many matching, stratification, multivariate adjustment) were evaluated using the full study cohort.
Our main analysis included patients with a history of amputations.
Our hdPS estimation model included history of amputations as a covariate because it was considered a significant risk factor for subsequent events. The goal with hdPS was to ensure both SGLT2i and DPP4i groups were similar at the start of follow-up. In a sensitivity analysis, we excluded patients with any amputation at baseline from the study cohort. Propensity scores were re-estimated and 1:1 matching re-performed in this subpopulation and the risk of amputations was determined in patients with no prior amputations.
Study and analytic datasets were developed using SAS software 
| RESULTS
Our study cohort initially included 137 012 patients that met the selection criteria (Figure 1 ). Prior to matching, the two groups were different in baseline characteristics (Tables S2 and S3 In subgroup analyses we found that the overall incidence rate of amputations was higher in the groups at a higher risk for amputations (age >=66 years, peripheral vascular disease at baseline, and with at least one vascular complication of diabetes at baseline) compared to low-risk categories, but the risk was similar by exposures ( Figure 2 ). In contrast, within the subgroups at low risk for amputations, there were excess amputations in patients treated with SGLT2i. Results from sensitivity analyses were consistent with the findings from the primary analysis. Redefining our outcome as nontraumatic below knee-level amputations did not change the effect estimate ( Figure 3 ). Extending the risk period for treatment effect beyond 30 days after the end of treatment resulted in attenuation of the effect estimate towards the null. Alternate approaches to control for confounding with hdPS (stratification, multivariate adjustment) did not change our findings. Comparisons using one-to-many matching with the hdPS were not included as the two groups were not balanced on baseline covariates.
There were 178 patients in the study cohort (n = 137 012) with a history of amputation at baseline. After excluding these patients (n = 136 834) and re-estimating propensity scores, the matched cohort included 60 350 patients, of whom 60 had an outcome (32 exposed/28 unexposed). Among patients with no history of amputations, the incidence rate of amputations after treatment initiation 
| DISCUSSION
We conducted an observational study to investigate the risk of amputations associated with the use of SGLT2i. Our cohort included commercially insured patients who were on average aged 55 years and newly initiating a SGLT2i or DPP4i. Patients were followed from initiation of treatment for a median of 0.6 years, over which we observed 60 amputations, 36 in the SGLT2i arm and 24 in the DPP4i arm, resulting in a 38% increased risk (CI 0.83-2.31), although the CI for the HR included 1.0. While our finding was not statistically significant, it does not rule out a potential for harm. Our CI included 1.97, the effect size observed for amputations in the CANVAS trials.
The CANVAS trials, which reported a 2-fold increase in amputation risk with canagliflozin, studied patients that were older (average age 63 years vs. 55 years) and sicker (65.6% with cardiovascular disease vs. 13.3%) than those in our cohort. Moreover, patients in CANVAS had a greater prevalence of risk factors for amputations.
A fifth of the CANVAS population had a history of peripheral vascular disease (vs. 4.5% in our cohort) and 2.5% had a history of amputation (vs. 0.18% in our cohort). In CANVAS, randomization balanced the distribution of these risk factors between the canagliflozin and placebo
arms, yet there were excess amputations in the canagliflozin arm, indicating a harmful drug effect. Our study used hdPS to balance baseline characteristics between groups and does not rule out an increased risk of amputations in younger and relatively healthier patients initiating SGLT2i.
The point estimate and CI from our primary analysis overlaps with those reported by Yuan et al. 18 and Udell et al., 19 known to exaggerate drug effects. 21 For this reason, our study defined new use as no baseline use of either study drug. In contrast, The strength of our study lies in its active comparator, new user (ACNU) design. 37 By choosing a viable therapeutic alternative as our comparator we compared patients at a similar level of disease severity. By anchoring the start of follow-up time at treatment initiation for both index and comparator groups, we avoided potential misclassification of person-time. The ACNU design was selected to limit the influence of confounding by indication, healthy user bias, and other forms of selection and time-related biases common in observational research. Moreover, we used hdPS matching to achieve balance between our treatment and comparison groups. High dimensional propensity scores have been shown to reduce the extent of residual confounding from unmeasured factors by using a large number of empirically selected proxies. 29 Additionally, we analysed our data under an as-treated approach, taking advantage of refill data to continually assess exposure to study drugs. 22 Not accounting for treatment discontinuation could bias the effect toward the null, as observed in our sensitivity analyses. In contrast, primary results reported by Yuan et al. 18 and Udell et al. 19 were under intent-to-treat. The CANVAS trial noted attenuation in the harmful effect of canagliflozin when patients were stratified by their history of amputations (HR in those with prior history 2.15 (1.11-4.19 ) and in those without 1.88 (1.27-2.78)). Due to the small number of patients in our study with a history of amputations, we were unable to perform a similar stratified analysis. Instead, we restricted our study cohort to those without amputations at baseline. We also note attenuation in the effect. It is unclear to us if any potential harmful effects of SGLT2i are modified by a history of amputations as the populations in our primary (HR 1.38) and sensitivity (HR 1.04) analyses are not the same.
Research in the future must continue on the risk of amputations, stratified by history of amputations.
There are several limitations to our study which must be considered when interpreting our findings. We lacked important clinical (HbA1C, duration of diabetes, BMI) and sociodemographic (race, ethnicity, socioeconomic status) information in our data, which limited our ability to control for underlying disease severity. This means that despite the use of an ACNU design and hdPS, there may have been some residual confounding by unmeasured factors. Moreover, diagnostic and procedural codes in administrative data are susceptible to errors and inaccuracies. Our drug data reflect dispensing and not actual ingestion. Nevertheless, there is no reason to believe that this potential misclassification of covariates occurs in a differential manner.
We conducted a large active comparator, new user cohort study and attempted to minimize confounding and time-related biases often present in observational research of antidiabetic medications. The incidence rate of amputations was higher in patients initiating SGLT2i compared with those initiating DPP4i, but the risk of amputations was not statistically significant. However, we remain unable to rule out the potential for harm. Our confidence intervals indicate the possibility of a 1.97-fold increased risk for amputations found in the CANVAS trials that resulted in a safety alert from the U.S. FDA. Our findings warrant additional observational research designed to limit the influence of time-related biases. Findings from multiple similar studies can then be synthesized in meta-analyses to clarify this ongoing concern to providers and patients with diabetes, and inform decision-making in clinical practice.
